Breast Cancer

Laura Yeager reflects on losses from theft and cancer, showing how resilience grows and gratitude emerges even after life's hardest setbacks.

CURE spoke with a provider and a survivor about the potential power of minimal residual disease testing.

CURE spoke with breast cancer survivor Mary Royal about her cancer journey in a multipart interview.

CURE spoke with Dr. Kathie-Ann Joseph about the importance of personalized, multidisciplinary treatments when caring for patients with breast cancer.

Dr. Sue Hwang explains how she went from a care provider who helped others through their cancer journeys to a patient facing a cancer diagnosis of her own.

CURE sat down with Dr. Kathie-Ann Joseph to discuss surgical advancements for individuals with breast cancer.

NCCN Guidelines now recommend Trodelvy as a category 1 first-line option for PD-L1–negative metastatic TNBC following phase 3 trial results.

The FDA granted Breakthrough Therapy status to zovegalisib plus Faslodex for patients with PIK3CA-mutated HR+/HER2- advanced breast cancer.

The FDA accepted a supplemental biologics license application and granted priority review for Datroway for adults unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.

CURE sat down with Dr. Kathie-Ann Joseph to discuss surgical advancements for individuals with breast cancer.

Clinical trial data shows that the protein CD47 may predict how well evorpacept works for patients with metastatic breast cancer.

Biotin supplements used for cancer-related hair loss may interfere with key blood tests, risking inaccurate results and altered care decisions.

Minimal residual disease testing can offer psychological comfort to patients and survivors as well as insight into potential treatment strategies for care providers.

Adding Ibrance to maintenance therapy extends the time some patients with metastatic breast cancer live without their disease progressing.

I’m preparing for something I once only dreamed about: my final visit to the cancer treatment center.

Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.

Researchers found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did not receive the guideline-recommended standard of care treatment.

Dr. Anne Peled, a two-time breast cancer survivor, underwent a sensation-preserving mastectomy, a procedure she co-developed.

Dr. Anne Peled shares advice for patients and dispelled myths related to cancer survivorship.

If you’re struggling out there, feeling a little broken inside, I see you. And if you’re not, man, I wish I were you.

This weekend, January 30 - February 1, join thousands of runners, walkers, survivors and spectators for the 19th Annual DONNA Marathon Weekend.

Among patients with advanced breast cancer, levels of circulating tumor DNA before treatment may predict their response to targeted therapy.

For Ashliann Mazeika, a diagnosis at 24 led to a decade-long treatment journey affirmed by the Breast Cancer Index test.

MammaPrint and BluePrint tests may help identify HR+/HER2– early-stage breast cancer patients likely to benefit from anthracycline-based chemotherapy.

Dr. Anne Peled co-developed the sensation-preserving mastectomy she received after her second diagnosis of breast cancer.